Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586460 | 0.82 | ALDH1A1 (0.66) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL12303993 | 0.80 | MEN1 (0.49) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL18596101 | 0.77 | ALDH1A1 (0.58) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL8294492 | 0.76 | ALDH1A1 (0.73) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL14844440 | 0.76 | ALDH1A1 (0.73) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL3589515 | 0.75 | MEN1 (0.55) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL18427068 | 0.74 | ALDH1A1 (0.54) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL14262602 | 0.72 | MEN1 (0.73) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL3397464 | 0.72 | ALDH1A1 (0.73) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 | |
| SCHEMBL8294486 | 0.72 | LDHA (1.00) | MEN1ALDH1A1KMT2AL3MBTL1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256109-A1 | Azetidines As EP2 Antagonists | SKERRATT SARAH ELIZABETH | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256109-A1 | Azetidines As EP2 Antagonists | PTGER2, PTGER1, PTGDR2 | MEN1 1016/4885ALDH1A1 544/4885KMT2A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.